Curaleaf International Launches CPD-Accredited Education Platform for UK Cannabis Prescribers
#70 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
UK clinicians now have access to structured, accredited education on cannabis pharmacology and prescribing, which is essential given the limited formal training in medical schools and the growing number of patients seeking cannabis-based treatments. This platform addresses a critical knowledge gap that directly impacts clinical decision-making around patient selection, dosing, drug interactions, and monitoring of cannabis therapies. Clinicians who complete this education can better counsel patients on realistic efficacy expectations, identify appropriate candidates for treatment, and reduce prescribing errors in an emerging therapeutic area.
Curaleaf International has launched a continuing professional development (CPD) accredited education platform designed to improve knowledge and competency among UK healthcare providers prescribing cannabis-based medicinal products. The curriculum addresses foundational gaps in cannabis pharmacology, including phytocannabinoid science and endocannabinoid system physiology, which are critical knowledge areas for clinicians responsible for patient selection, dosing, and monitoring. This initiative responds to documented educational deficiencies in medical training regarding cannabis therapeutics, which has limited prescriber confidence and potentially constrained clinical adoption of cannabis-based treatments for eligible patients. CPD-accredited education helps ensure that prescribers can practice evidence-based cannabis medicine, understand drug interactions, recognize contraindications, and counsel patients appropriately on efficacy and safety. The availability of structured, accredited training may increase the quality and consistency of cannabis prescribing across UK clinical settings while supporting professional development requirements. Clinicians should consider engaging with accredited educational resources to enhance their competency in cannabis therapeutics and provide more informed, evidence-based recommendations to their patients.
“While continuing medical education platforms are valuable for keeping prescribers current, I’d note that this particular offering comes from an industry actor with financial interests in cannabis sales, so clinicians should evaluate the curriculum against independent, peer-reviewed literature and ensure they’re not inadvertently absorbing marketing alongside education.”
💊 The introduction of accredited continuing professional development for cannabis prescribers addresses a genuine knowledge gap in UK medical practice, as many practitioners have limited formal training in cannabinoid pharmacology or patient selection for cannabis-based medicines. However, clinicians should recognize that educational content developed by industry stakeholders may reflect commercial interests alongside scientific rigor, warranting careful evaluation of curriculum scope, evidence quality, and balance between established efficacy and emerging claims. The foundational science covered in such programs is valuable, yet prescribers must remember that high-quality randomized controlled trial evidence remains limited for most cannabis indications outside refractory epilepsy and chemotherapy-induced nausea, and that patient phenotyping, drug interactions with concurrent medications, and monitoring for adverse effects remain incompletely characterized. A practical approach involves using accredited education as one input among systematic review literature and established clinical guidelines when developing cannabis prescribing competence, while maintaining appropriate skepticism about
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
